Evotec AG - Product Pipeline Review - 2015

Published: Apr, 2015 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Evotec AG - Product Pipeline Review - 2015

Summary 

Global Markets Direct's, 'Evotec AG - Product Pipeline Review - 2015', provides an overview of the Evotec AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Evotec AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Evotec AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Evotec AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Evotec AG's pipeline products

Reason To Buy 

- Evaluate Evotec AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Evotec AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Evotec AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Evotec AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Evotec AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Evotec AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Evotec AG Snapshot 7
Evotec AG Overview 7
Key Information 7
Key Facts 7
Evotec AG - Research and Development Overview 8
Key Therapeutic Areas 8
Evotec AG - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Evotec AG - Pipeline Products Glance 17
Evotec AG - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Evotec AG - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Evotec AG - Drug Profiles 21
EVT-201 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
EVT-401 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Drug to Inhibit KDM for Oncology 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Drugs for Endometriosis 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Drugs for Multiple Sclerosis 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
EVT-501 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule to Inhibit PDE10a for Schizophrenia and Psychosis 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules for Pain 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Drug for Kidney Diseases 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Drugs for Alzheimer's Disease 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drugs to Inhibit FGFR3 for Bladder Cancer 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Drugs to Inhibit Isocitrate Dehydrogenase for Cancer 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Drugs to Target EEM for Type 1 Diabetes and Type 2 Diabetes 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Induced Pluripotent Stem Cells for Amyotrophic Lateral Sclerosis 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Inhibit PGB for Bacterial Infections 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules for Chronic Kidney Disease 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules for Dysferlinopathies 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules for Glioblastoma Multiforme 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small molecules for Huntington Disease 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules for Inflammation 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecules for Multiple Sclerosis 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules for Neurodegeneration 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules for Solid Tumor and Leukemia 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Evotec AG - Pipeline Analysis 45
Evotec AG - Pipeline Products by Target 45
Evotec AG - Pipeline Products by Route of Administration 46
Evotec AG - Pipeline Products by Molecule Type 47
Evotec AG - Pipeline Products by Mechanism of Action 48
Evotec AG - Recent Pipeline Updates 49
Evotec AG - Dormant Projects 50
Evotec AG - Discontinued Pipeline Products 51
Discontinued Pipeline Product Profiles 51
EVT-301 51
RG-1577 51
ocaperidone 51
REN-1654 51
REN-213 51
REN-850 51
Evotec AG - Company Statement 52
Evotec AG - Locations And Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables

Evotec AG, Key Information 7
Evotec AG, Key Facts 7
Evotec AG - Pipeline by Indication, 2015 9
Evotec AG - Pipeline by Stage of Development, 2015 11
Evotec AG - Monotherapy Products in Pipeline, 2015 12
Evotec AG - Partnered Products in Pipeline, 2015 13
Evotec AG - Partnered Products/ Combination Treatment Modalities, 2015 14
Evotec AG - Out-Licensed Products in Pipeline, 2015 15
Evotec AG - Out-Licensed Products/ Combination Treatment Modalities, 2015 16
Evotec AG - Phase II, 2015 17
Evotec AG - Phase I, 2015 18
Evotec AG - Preclinical, 2015 19
Evotec AG - Discovery, 2015 20
Evotec AG - Pipeline by Target, 2015 45
Evotec AG - Pipeline by Route of Administration, 2015 46
Evotec AG - Pipeline by Molecule Type, 2015 47
Evotec AG - Pipeline Products by Mechanism of Action, 2015 48
Evotec AG - Recent Pipeline Updates, 2015 49
Evotec AG - Dormant Developmental Projects,2015 50
Evotec AG - Discontinued Pipeline Products, 2015 51
Evotec AG, Subsidiaries 53